REFERENCES
The Supera™ Stent has been studied in over 2,000 patients worldwide in the SUPERB trial and 16 retrospective studies. Notably, in all of the 17 studies, the Supera™ Peripheral Stent showed durable results with zero fractures at 1 year.1,15-30
At 1 year the Supera™ Stent demonstrated primary patency of 91% when nominally* deployed. At 3 years, freedom from targeted lesion revascularization (TLR) was 94% when nominally* deployed.1
When nominally deployed*
When nominally deployed*
*Nominal deployment is defined as the stent length upon deployment being within +/- 10% of the labeled stent length. These data are from a non-powered post-hoc analysis. KM = Kaplan-Meier.
Supera Stent has demonstrated unmatched clinical outcomes in comparison to other US pivotal trial results which primarily included simple lesions.*,1-12
1-Year Patency (KM) | 3-Year Freedom from TLR | |||
---|---|---|---|---|
91% | Supera™ Stent Nominal1 |
94% | Supera™ Stent Nominal1 |
|
87% | Eluvia‡12 | Not Reported | Eluvia‡ | |
84% | Zilver PTX‡2 | 84% | Zilver PTX‡2 | |
83% | Misago‡11 | Not Available | Misago‡ | |
81% | LifeStent‡3 | 76% | LifeStent‡4 | |
80% | S.M.A.R.T.‡5 | 79% | S.M.A.R.T.‡6 | |
77% | EverFlex‡7 | 70% | EverFlex‡8 | |
74% | Innova‡9 | Not Reported | Innova‡ | |
67% | Pulsar‡10 | Not Reported | Pulsar‡ |
* Study reported with a majority as Trans-Atlantic Inter-Society Consensus Document (TASC) A&B lesion and/or majority as Rutherford Class 2 and 3.
NOTE: Results from clinical trials are not directly comparable. Information provided for educational purposes only.
With some peripheral stents, increasing lesion lengths can lead to decreasing patency rates.31 The Supera™ Stent stands apart for its consistently high patency rates in lesions spanning lengths from 5.3 cm up to 28.0 cm*.
*Published data was included if lesion length and patency were both available.
Note: Results from different clinical trials are not directly comparable. Information provided for educational purposes only.
Whether treating simple (TASC A&B) or complex (TASC C&D) lesions, the Supera™ Stent is associated with impressive, consistent patency performance data.13-15,32
Simple | |||
---|---|---|---|
![]() |
Trial/Study | MUNICH REGISTRY13 | SUPERB32 |
Lesion Length | 5.3cm | 7.8cm | |
TASC A&B Lesions | 100% | 94% | |
1-Yr Patency |
86.7% | 90.5% | |
Sites | Single Center | Multicenter (46 sites) | |
# Patients | 70 | 264 |
TASC: Trans-Atlantic Inter-Society Consensus
Complex | |||
---|---|---|---|
![]() |
Trial/Study | ST. LOUIS15 | SUPERSUB14 |
Lesion Length | 5.3cm | 7.8cm | |
TASC C&D Lesions | 78% | 100% | |
CTOs | Unknown | 100% | |
1-Yr Patency |
85.6% | 94.1% | |
Sites | Single Center | Single Center | |
# Patients | 48 | 34 |
TASC: Trans-Atlantic Inter-Society Consensus
REFERENCES
MAT-2008210 v1.0
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Precautions
Please be sure to read it.
The following pages are intended for medical professionals and provide information on the proper use of products (medical devices, etc.) of Abbott Medical Japan GK.
The information provided here is not intended to provide information to patients and the general public.
Are you a healthcare professional?
Test